FDA Oversight of Compounded GLP-1 Drugs, Active
Summary
HHS OIG announced an active study to assess FDA's oversight of compounded glucagon-like peptide-1 receptor agonist (GLP-1) drugs. The study will examine FDA's inspection of compounding facilities and use of available data to identify and address potential risks to patients. GLP-1 drugs were on FDA's drug shortage list from 2022 to 2025, during which compounding facilities were permitted to produce copies. The study is estimated for completion in fiscal year 2028.
What changed
HHS OIG has announced an active study to assess FDA's oversight of compounded GLP-1 drugs. The Office of Evaluation and Inspections will examine the extent to which FDA inspects compounders and leverages available data to identify and address potential risks to patients. The study comes after large-scale compounding of GLP-1 drugs occurred during the 2022-2025 shortage period.\n\nAffected parties including pharmaceutical companies, healthcare providers, and patients should monitor this study for potential recommendations that could inform future FDA regulatory actions. The estimated completion date of fiscal year 2028 suggests significant findings may emerge that influence compounding pharmacy practices and FDA oversight protocols.
What to do next
- Monitor for OIG study findings and recommendations
- Review internal compounding practices and compliance procedures
- Stay informed about FDA regulatory developments for GLP-1 compounds
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Beta This is a new resource
-
your [feedback]() will help us improve it.
FDA’s Efforts To Oversee and Mitigate the Risks of Compounded GLP-1 Drugs
Announced on
04/15/2026
| Last Modified on
04/15/2026
| Project Number: OEI-01-25-00450
Status Active Agency Food and Drug Administration
OBJECTIVE
Recent large-scale compounding of glucagon-like peptide-1 receptor agonists (GLP-1 drugs) has highlighted challenges the Food and Drug Administration (FDA) faces in overseeing the quality of these products and mitigating risks to patients. From 2022 to 2025, certain GLP-1 drugs were on FDA’s drug shortage list, so compounding facilities were allowed to produce copies of these drugs. Although the shortages ended in early 2025, some compounding facilities may still be compounding large quantities of GLP-1 drugs. This study will assess FDA's efforts to oversee the compounding of GLP-1 drugs, including the extent to which FDA inspects compounders and leverages available data to identify and address potential risks.
TIMELINE
- April 15, 2026 Announced
- Today Office of Evaluation and Inspections In-Progress
- Est FY2028 Estimated Fiscal Year for Project Completion Work Plan Type Office of Evaluation and Inspections HHS Agencies Food and Drug Administration Issue Areas Food, Drug and Device Safety Prescription Drug Target Groups - Financial Groups Other Funding
Related changes
Get daily alerts for HHS OIG Work Plan
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from HHS OIG.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when HHS OIG Work Plan publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.